AG真人官方

Silexion Therapeutics (SLXN) filed an 8-K announcing a 1-for-15 reverse share split effective after the 28-Jul-25 close. Authorized capital stays US$20,000 but is now divided into 1,481,482 ordinary shares; par value rises to US$0.0135. All issued and outstanding shares are reduced proportionally and will begin trading on a split-adjusted basis under the same ticker at the 29-Jul-25 open. The new ordinary-share CUSIP is G1281K 130.

The company simultaneously delivered a Warrant Adjustment Notice. Each pre-split warrant is now exercisable for 1/15th of a share, and the exercise price is lifted 15脳 to US$1,552.50 per post-split share. Fractional entitlements will be rounded up at the broker (DTC participant) level. Warrant CUSIP (G1281K 114) and ticker (SLXNW) are unchanged.

The split was approved at the 14-Jul-25 AGM and effected through an amendment to the Amended & Restated Memorandum of Association, filed 28-Jul-25. Items 3.03 and 5.03 detail the warrant modifications and charter amendment, while Item 8.01 incorporates these events by reference.

Silexion Therapeutics Corp (SLXN) will hold an extraordinary general meeting in Aug-2025 to vote on a single item: increasing authorised share capital to US$121,500 divided into 9,000,000 ordinary shares (par US$0.0135) from the post-reverse-split level of 1,481,482 shares.

The board says the extra 7.5 m shares are essential to (1) regain and thereafter maintain compliance with Nasdaq Listing Rule 5550(b)(1) 鈥� minimum US$2.5 m shareholders鈥� equity by 19-Sep-2025 鈥� following a favourable Nasdaq hearings-panel decision on 7-Jul-2025, and (2) fund pre-clinical/clinical RNAi programs and potential business-development deals. Current capacity is only 529,302 unissued shares, viewed as inadequate for equity raises, warrant/option exercises, conversion of a US$3.433 m sponsor note and employee incentives.

The proposed authorisation represents a 507% increase in total authorised shares. The board unanimously recommends voting FOR. Failure would likely trigger Nasdaq delisting. Risks highlighted include substantial dilution, potential share-price pressure and anti-takeover uses of the new shares.

On July 16 2025 Silexion Therapeutics Corp ("SLXN") filed an 8-K announcing a 1-for-15 reverse share split affecting all issued, outstanding and authorized ordinary shares. The split will be effected automatically after market close on 28 Jul 2025, and the shares will begin trading on a split-adjusted basis on Nasdaq at the open on 29 Jul 2025; the ticker remains "SLXN".

• Every 15 existing shares convert into 1 new share.
• Par value increases from $0.0009 to $0.0135 per share.
• No fractional shares will be issued; DTC positions will be rounded up to the nearest whole share.

The Board鈥檚 goal is to raise the per-share price to maintain compliance with Nasdaq Capital Market listing standards. Warrants ("SLXNW") are expected to be adjusted pursuant to their terms. Additional details are provided in the press release attached as Exhibit 99.1.

Silexion Therapeutics Corp (NASDAQ: SLXN) filed a Form 8-K on 9 July 2025 under Item 7.01 (Regulation FD). The sole purpose of the filing is to furnish 鈥� not file 鈥� a press release (Exhibit 99.1) titled 鈥淪ilexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines.鈥� No additional financial statements or transaction details are included, and the company explicitly states the information is not incorporated by reference into other Securities Act filings.

Key points

• The press release reports positive preclinical efficacy for SIL204 in human lung cancer cell lines.
• The disclosure is furnished under Regulation FD, ensuring simultaneous public access to the information.
• No revenue, cost, guidance, or clinical-stage data accompany the announcement.
• Exhibits attached: 99.1 (press release) and 104 (Inline XBRL cover data).

Investors receive confirmation of encouraging scientific data but must consult Exhibit 99.1 for experimental specifics, as the 8-K itself contains minimal detail.

Silexion Therapeutics Corp (NASDAQ: SLXN) announced that a Nasdaq hearings panel has granted the company continued listing status, but with conditions. Effective July 8, 2025, the company鈥檚 ordinary shares and warrants will move from the Nasdaq Global Market to the Nasdaq Capital Market, keeping their current tickers 鈥沦尝齿狈鈥� and 鈥沦尝齿狈奥.鈥�

The panel鈥檚 decision hinges on Silexion鈥檚 ability to achieve and maintain at least $2.5 million in shareholders鈥� equity by September 19, 2025 and to demonstrate that level in an SEC filing that includes a balance sheet dated within 60 days of submission. Nasdaq will retain jurisdiction over the company鈥檚 listing status until November 18, 2025; any further rule breaches before that date must be accompanied by an additional compliance plan for panel review.

Silexion also disclosed a potential bid-price deficiency (closing price below $1.00 for 30 consecutive trading days). Management intends to remedy this by executing a 1-for-15 reverse share split shortly after its reconvened annual general meeting on July 14, 2025, pending shareholder approval, with the split expected to take effect on or about July 25, 2025.

Key investor takeaway: Listing is preserved, but the company must raise equity or otherwise strengthen its balance sheet, complete the reverse split, and avoid additional rule breaches. Failure to meet these milestones could trigger delisting despite the current reprieve.